Diabetes and Cancer Epidemiology
Pp. 98-104 (7)
It has been proposed that diabetes was associated with an increased risk of cancer mortality
and morbidity. Complex mechanisms are involved in the association between diabetes and cancer.
Metformin has been suggested to reduce the risk of cancer incidence (Hazard ratio 0.63 (95% CI 0.53-
0.75)) or cancer mortality (Hazard ratio 0.43 (95% CI 0.23-0.80)), but insulin or sulfonylurea is
suspected to increase the risk of cancer incidence (Hazard ratio 1.36 (95% CI 1.19-1.54)) or cancer
mortality (Hazard ratio 1.30 (95% CI 1.10-1.60)). Evidences on these issues are reviewed and
summarized in this chapter.
Diabetes, anti-diabetic drugs, cancer motality and morbidity.
Department of Endocrinology and Metabolism, Peking University People’s Hospital, 11 Xizhimen South Street, 100044, Beijing, China and Department of Public Health, Hjelt Institute, University of Helsinki, PL41, Mannerheimintie 172, 00014, Helsinki, Finland